Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 15/20 | 0.85 |
| ▸ | JAK1 | P23458 | 14/20 | 0.85 |
| ▸ | SYK | P43405 | 6/20 | 0.61 |
| ▸ | JAK2 | O60674 | 2/20 | 0.51 |
| ▸ | EGFR | P00533 | 2/20 | 0.51 |
| ▸ | LCK | P06239 | 2/20 | 0.51 |
| ▸ | LYN | P07948 | 2/20 | 0.51 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.51 |
| ▸ | CDK2 | P24941 | 2/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.48 |
| ▸ | CDK1 | P06493 | 2/20 | 0.47 |
| ▸ | CDC7 | O00311 | 1/20 | 0.47 |
| ▸ | PLK4 | O00444 | 1/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.47 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1474227 | 0.92 | JAK3 (1.00) | JAK3JAK1SYKJAK2EGFR | |
| SCHEMBL1474333 | 0.91 | JAK3 (0.80) | JAK3JAK1SYKJAK2EGFR | |
| SCHEMBL1474922 | 0.90 | JAK3 (0.85) | JAK3JAK1SYKJAK2EGFR | |
| SCHEMBL4006175 | 0.83 | JAK3 (0.85) | JAK3JAK1SYKJAK2EGFR | |
| SCHEMBL1477012 | 0.82 | JAK1 (0.60) | JAK3JAK1SYKCDK2CCNA2 | |
| SCHEMBL1476669 | 0.82 | JAK3 (1.00) | JAK3JAK1SYKJAK2EGFR | |
| SCHEMBL4000402 | 0.79 | JAK3 (0.62) | JAK3JAK1SYKJAK2EGFR | |
| SCHEMBL658283 | 0.77 | SYK (0.73) | JAK3JAK1SYKJAK2EGFR | |
| SCHEMBL2785795 | 0.77 | SYK (0.73) | JAK3JAK1SYKJAK2EGFR | |
| SCHEMBL1475290 | 0.76 | JAK3 (0.62) | JAK3JAK1SYKJAK2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221089-A1 | Prevent transplant rejection; autoimmune diseases | RIGEL PHARMACEUTICALS, INC. | 2008-09-11 | — | — | US | claimed |
| US-20070203161-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2007-08-30 | — | — | US | claimed |
| US-11667611-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-20190256476-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2019-08-22 | — | — | US | disclosed |
| US-20170121291-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2017-05-04 | — | — | US | disclosed |
| US-9593082-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-7915273-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-20100152218-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20080221089-A1 | Prevent transplant rejection; autoimmune diseases | RIGEL PHARMACEUTICALS, INC. | 2008-09-11 | — | — | US | disclosed |
| WO-2008079907-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| US-20070203161-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11667611-B2 | Compositions and methods for inhibition of the JAK pathway | JAK3, JAK2, JAK1 | JAK3 1/4885JAK1 3/4885SYK 62/4885 |
| US-20170121291-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | JAK3 1/4885JAK1 3/4885SYK 62/4885 |
| US-20190256476-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | JAK3 1/4885JAK1 3/4885SYK 62/4885 |
| US-20070203161-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | JAK3 1/4885JAK1 3/4885SYK 62/4885 |
| US-20080221089-A1 | Prevent transplant rejection; autoimmune diseases | JAK3, JAK1, JAK2 | JAK3 1/4885JAK1 2/4885SYK 233/4885 |
| US-20100152218-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | JAK3 1/4885JAK1 3/4885SYK 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.